Obstructive Sleep Apnea Syndrome Clinical Trial
— AIRSTIMOfficial title:
Upper AIRway Implanted Nerve STIMulation Therapy: A Breakthrough in Obstructive Sleep Apnea Therapy
NCT number | NCT03844295 |
Other study ID # | 38RC18.030 |
Secondary ID | |
Status | Recruiting |
Phase | N/A |
First received | |
Last updated | |
Start date | March 21, 2019 |
Est. completion date | January 2023 |
Continuous positive airway pressure (CPAP) is the gold standard to normalize breathing during sleep in patients with obstructive sleep apnea syndrom (OSA). Many patients will not tolerate or will not accept CPAP. Implanted nerve stimulation is a novel therapy for OSA patients that restores the upper airway potency using unilateral XII nerve electric stimulation. The principal objective of this study is short-term efficacy of a new treatment for OSA on blood pressure variability during sleep.
Status | Recruiting |
Enrollment | 6 |
Est. completion date | January 2023 |
Est. primary completion date | August 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 80 Years |
Eligibility | Inclusion Criteria: - Patient aged 18 to 80 years old - Patient with moderate to severe OSA based on an established diagnosis of OSA (15=AHI<65) by polysomnography or respiratory polygraphy not older thant three years. - Patient with moderate to severe OSA naïve of treatment or with difficulty accepting or adhering to CPAP treatment. - Willing and capable to have stimulation hardware permanently implanted, and to use the patient programmer to activate the stimulation - Willing and capable to return for all follow-up visits and conduct sleep studies at home, including the evaluation procedures and filling out questionnaires - Willing and capable of providing written informed consent. Exclusion Criteria: - Any anatomical finding that would compromise the performance of upper airway stimulation, such as the presence of complete concentric collapse of the soft palate - Have any condition or procedure that has compromised neurological control of the upper airway - Unable to operate the patient programmer - Pregnant or plan to become pregnant, and breastfeeding women - Require magnetic resonance imaging (MRI) - Have an implantable device that may be susceptible to unintended interaction with the Inspire system. Additional exclusions for study purposes only - Body Mass Index (BMI) of >32 - Central + mixed apneas > 25% of the total apnea-hypopnea index (AHI) - Neuromuscular disease - Hypoglossal-nerve palsy - Severe restrictive or obstructive pulmonary disease - Moderate-to-severe pulmonary arterial hypertension - Severe valvular heart disease - New York Heart Association class III or IV heart failure - Recent myocardial infarction or severe cardiac arrhythmias (within the past 6 months) - Persistent uncontrolled hypertension despite medication use - Coexisting nonrespiratory sleep disorders that would confound functional sleep assessment - Any chronic medical illness or condition that contraindicates a surgical procedure under general anesthesia, as judged by the clinical study Investigator - a terminal illness with life expectancy < 12 months - Active psychiatric disease (psychotic illness, major depression, or acute anxiety attacks) which prevents subject compliance with the requirements of the investigational study testing - Radiotherapy or ablation therapy of the head and/or neck - Surgical resection for cancer or congenital malformations in the larynx, tongue, or throat(with exception of tonsillectomy and/or adenoidectomy) - Previous surgery within 3 months performed on the soft-palate tissue - Obvious fixed upper airway obstructions (tumors, polyps, unilateral nasal obstruction) - Need for chronic supplemental oxygen therapy for any other reason, pO2 (partial pressure of oxygen) < 55 mm Hg - Clinical evidence of severe renal failure (Stage 4 or 5) undergoing dialysis or expected to institute dialysis within 6 months - Patients on medication that may alter consciousness, the pattern of respiration or sleep architecture (for example, benzodiazepiones, opiates, neuroleptics, prescription stimulants, phenothiazine, or any form of chemical substance abuse) - Patients taking blood thinning medications (for example warfarin, aspirin, plavix or other blood thinning agents which cannot be safety stopped or bridged temporarily to allow surgery to take place) - Any other reason for the investigator deems that the subject is unfit for participation in the study - Subject in exclusion period for another study - Subject under administrative or judicial control. |
Country | Name | City | State |
---|---|---|---|
France | UniversityHospitalGrenoble | Grenoble |
Lead Sponsor | Collaborator |
---|---|
University Hospital, Grenoble | Inspire Medical Systems, Inc. |
France,
Berry RB, Budhiraja R, Gottlieb DJ, Gozal D, Iber C, Kapur VK, Marcus CL, Mehra R, Parthasarathy S, Quan SF, Redline S, Strohl KP, Davidson Ward SL, Tangredi MM; American Academy of Sleep Medicine. Rules for scoring respiratory events in sleep: update of the 2007 AASM Manual for the Scoring of Sleep and Associated Events. Deliberations of the Sleep Apnea Definitions Task Force of the American Academy of Sleep Medicine. J Clin Sleep Med. 2012 Oct 15;8(5):597-619. doi: 10.5664/jcsm.2172. — View Citation
Eastwood PR, Barnes M, Walsh JH, Maddison KJ, Hee G, Schwartz AR, Smith PL, Malhotra A, McEvoy RD, Wheatley JR, O'Donoghue FJ, Rochford PD, Churchward T, Campbell MC, Palme CE, Robinson S, Goding GS, Eckert DJ, Jordan AS, Catcheside PG, Tyler L, Antic NA, Worsnop CJ, Kezirian EJ, Hillman DR. Treating obstructive sleep apnea with hypoglossal nerve stimulation. Sleep. 2011 Nov 1;34(11):1479-86. doi: 10.5665/sleep.1380. — View Citation
Gagnadoux F, Fleury B, Vielle B, Pételle B, Meslier N, N'Guyen XL, Trzepizur W, Racineux JL. Titrated mandibular advancement versus positive airway pressure for sleep apnoea. Eur Respir J. 2009 Oct;34(4):914-20. doi: 10.1183/09031936.00148208. Epub 2009 Mar 26. — View Citation
Goding GS Jr, Tesfayesus W, Kezirian EJ. Hypoglossal nerve stimulation and airway changes under fluoroscopy. Otolaryngol Head Neck Surg. 2012 Jun;146(6):1017-22. doi: 10.1177/0194599812436472. Epub 2012 Feb 3. — View Citation
Lallukka T, Kaikkonen R, Härkänen T, Kronholm E, Partonen T, Rahkonen O, Koskinen S. Sleep and sickness absence: a nationally representative register-based follow-up study. Sleep. 2014 Sep 1;37(9):1413-25. doi: 10.5665/sleep.3986. — View Citation
Mayer P, Pépin JL, Bettega G, Veale D, Ferretti G, Deschaux C, Lévy P. Relationship between body mass index, age and upper airway measurements in snorers and sleep apnoea patients. Eur Respir J. 1996 Sep;9(9):1801-9. — View Citation
Mulgrew AT, Ryan CF, Fleetham JA, Cheema R, Fox N, Koehoorn M, Fitzgerald JM, Marra C, Ayas NT. The impact of obstructive sleep apnea and daytime sleepiness on work limitation. Sleep Med. 2007 Dec;9(1):42-53. Epub 2007 Sep 6. — View Citation
Mwenge GB, Dury M, Delguste P, Rodenstein D. Response of automatic continuous positive airway pressure devices in a normal subject. Eur Respir J. 2011 Jun;37(6):1530-3. doi: 10.1183/09031936.00139510. — View Citation
Oldenburg O, Lamp B, Faber L, Teschler H, Horstkotte D, Töpfer V. Sleep-disordered breathing in patients with symptomatic heart failure: a contemporary study of prevalence in and characteristics of 700 patients. Eur J Heart Fail. 2007 Mar;9(3):251-7. Epub 2006 Oct 5. — View Citation
Pépin JL, Tamisier R, Barone-Rochette G, Launois SH, Lévy P, Baguet JP. Comparison of continuous positive airway pressure and valsartan in hypertensive patients with sleep apnea. Am J Respir Crit Care Med. 2010 Oct 1;182(7):954-60. doi: 10.1164/rccm.200912-1803OC. Epub 2010 Jun 3. — View Citation
Schwartz AR, Barnes M, Hillman D, Malhotra A, Kezirian E, Smith PL, Hoegh T, Parrish D, Eastwood PR. Acute upper airway responses to hypoglossal nerve stimulation during sleep in obstructive sleep apnea. Am J Respir Crit Care Med. 2012 Feb 15;185(4):420-6. doi: 10.1164/rccm.201109-1614OC. Epub 2011 Dec 1. — View Citation
Somers VK, Dyken ME, Clary MP, Abboud FM. Sympathetic neural mechanisms in obstructive sleep apnea. J Clin Invest. 1995 Oct;96(4):1897-904. — View Citation
Strollo PJ Jr, Soose RJ, Maurer JT, de Vries N, Cornelius J, Froymovich O, Hanson RD, Padhya TA, Steward DL, Gillespie MB, Woodson BT, Van de Heyning PH, Goetting MG, Vanderveken OM, Feldman N, Knaack L, Strohl KP; STAR Trial Group. Upper-airway stimulation for obstructive sleep apnea. N Engl J Med. 2014 Jan 9;370(2):139-49. doi: 10.1056/NEJMoa1308659. — View Citation
Tamisier R, Pépin JL, Rémy J, Baguet JP, Taylor JA, Weiss JW, Lévy P. 14 nights of intermittent hypoxia elevate daytime blood pressure and sympathetic activity in healthy humans. Eur Respir J. 2011 Jan;37(1):119-28. doi: 10.1183/09031936.00204209. Epub 2010 Jun 4. — View Citation
Tamisier R, Tan CO, Pepin JL, Levy P, Taylor JA. Blood Pressure Increases in OSA due to Maintained Neurovascular Sympathetic Transduction: Impact of CPAP. Sleep. 2015 Dec 1;38(12):1973-80. doi: 10.5665/sleep.5252. — View Citation
Young T, Palta M, Dempsey J, Skatrud J, Weber S, Badr S. The occurrence of sleep-disordered breathing among middle-aged adults. N Engl J Med. 1993 Apr 29;328(17):1230-5. — View Citation
Young T, Peppard PE, Gottlieb DJ. Epidemiology of obstructive sleep apnea: a population health perspective. Am J Respir Crit Care Med. 2002 May 1;165(9):1217-39. Review. — View Citation
* Note: There are 17 references in all — Click here to view all references
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Short-term efficacy of a new treatment for OSA on systolic blood pressure variability during sleep | Change in the difference between delta nocturnal systolic blood pressure (difference between maximum and minimal nocturnal systolic blood pressure ; nocturnal period is defined from 10 pm to 7am). | one month treatment active versus non active treatment | |
Secondary | Short-term efficacy of a new treatment for OSA on mean-24h, daytime and nighttime blood pressure | Ambulatory 24h arterial blood pressure | one month treatment active versus non active treatment | |
Secondary | Clinical efficacy of this new treatment on OSA by Epworth sleepiness scale score | It's a self-administered questionnaire with 8 questions. Patients are asked to rate, on a 4-point scale (0-3), their usual chances of dozing off or falling asleep while engaged in eight different activities. The ESS score (the sum of 8 item scores, 0-3) can range from 0 to 24. The higher the ESS score, the higher that person has daytime sleepiness. | one month treatment active versus non active treatment | |
Secondary | Clinical efficacy of this new treatment on Apnea-Hypopnea Index measured by polysomnography | Apnea-Hypopnea Index expressed in number per hour | one month treatment active versus non active treatment | |
Secondary | Change in sympatho-vagal balance based on heart rate variability analysis | ECG polysomnography | one month treatment active versus non active treatment | |
Secondary | Self-reported changes in sleep and quality of life by SF-36 score | The SF-36 is a 36-item scale constructed to survey health status and quality of life (Ware & Sherbourne, 1992), assessing eight health concepts: limitations in Quality of life physical activities because of health problems; limitations in social activities because of physical or emotional problems; limitations in usual role activities because of physical health problems); bodily pain; general mental health (psychological distress and well-being); limitations in usual role activities because of emotional problems; vitality (energy and fatigue); and general health perceptions. The standard form of the instruments asks for participants to reply to questions according to how they have felt over the previous week. The items use Likert-type scales, some with 5 or 6 points and others with 2 or 3 points. The SF-36 has been widely used and has excellent psychometrics. | one month treatment active versus non active treatment | |
Secondary | Sleep latency assessed during a Maintenance of Wakefulness Test | Mean sleep latency from the 4 sessions of the Maintenance of Wakefulness Test | one month treatment active versus non active treatment | |
Secondary | Nocturnal pulse pressure assessed by Continuous Non-invasive Arterial Pressure monitoring | Pulse pressure variability indexe DeltaBP in mmHg. | one month treatment active versus non active treatment | |
Secondary | Short-term efficacy of a new treatment for OSA on diastolic blood pressure variability during sleep | Change in the difference between delta nocturnal systolic blood pressure (difference between maximum and minimal nocturnal systolic blood pressure ; nocturnal period is defined from 10 pm to 7am). | one month treatment active versus non active treatment | |
Secondary | Clinical efficacy of this new treatment on OSA by Pichot weakness scale score | It's a self-administered questionnaire with 8 questions. Patients are asked to rate, on a 5-point scale (0-4), their usual feeling of tiredness or weakness while engaged in eight different activities. The PWS score (the sum of 8 item scores, 0-4) can range from 0 to 32. The higher the PWS score, the higher that person has weakness. | one month treatment active versus non active treatment | |
Secondary | Clinical efficacy of this new treatment on nocturia | Assessment of nocturia number by nigt | one month treatment active versus non active treatment | |
Secondary | Clinical efficacy of this new treatment on morning asthenia | Patients are asked to assess, on a visual analogic scale morning asthenia. The items use a visual analogic scales from 0 to 10 points. | one month treatment active versus non active treatment | |
Secondary | Clinical efficacy of this new treatment on morning headache | Patients are asked to assess, on a visual analogic scale morning headache. The items use a visual analogic scales from 0 to 10 points. | one month treatment active versus non active treatment | |
Secondary | Clinical efficacy of this new treatment on snoring | Patients are asked to assess, on a visual analogic scale snoring. The items use a visual analogic scales from 0 to 10 points. | one month treatment active versus non active treatment | |
Secondary | Self-reported changes in sleep and quality of life by FOSQ score | This is a disease specific quality of life questionnaire to determine functional status in adults; measures are designed to assess the impact of disorders of excessive sleepiness on multiple activities of everyday living and the extent to which these abilities are improved by effective treatment. The 5 domains that the FOSQ measures are as follows: Activity level, vigilance, intimacy and sexual relationships, general productivity, social outcome, rate the difficulty of performing a given activity on a 4-point scale (no difficulty to extreme difficulty). | one month treatment active versus non active treatment | |
Secondary | Clinical efficacy of this new treatment on oxygen desaturation index measured by polysomnography | Oxygen desaturation index expressed in number | one month treatment active versus non active treatment | |
Secondary | Clinical efficacy of this new treatment on sleep efficacy measured by polysomnography | Sleep efficacy expressed by ratio of total sleep time on total sleep period | one month treatment active versus non active treatment |
Status | Clinical Trial | Phase | |
---|---|---|---|
Withdrawn |
NCT05164211 -
Didgeridoo Treatment to Improve Pharyngeal Compliance in Obstructive Sleep Apnea-hypopnea Syndrome in Children
|
N/A | |
Active, not recruiting |
NCT05049928 -
m-Rehab OSA : Impact of a Telerehabilitation Program Associated With CPAP on Severity Markers of Obstructive Sleep Apnea Syndrome
|
N/A | |
Not yet recruiting |
NCT04538274 -
Trained Patient Involvement to Promote the Resumption of CPAP in Patients Who Have Discontinued Its Use
|
N/A | |
Completed |
NCT02967367 -
Reliability of Consumer Sleep Trackers in Patients Suffering From Obstructive Sleep Apnea Syndrome
|
N/A | |
Completed |
NCT02180672 -
Steroids for Pediatric Apnea Research in Kids
|
Phase 3 | |
Recruiting |
NCT01561677 -
Consequences of Obstructive Sleep Apnea Syndrome (OSAS) After Ischemic Subtentorial Stroke.
|
N/A | |
Completed |
NCT01193738 -
Osteopathy and Obstructive Sleep Apnea Syndrome
|
N/A | |
Completed |
NCT01808508 -
Obstructive Sleep Apnea and Neurocognitive and Cardiovascular Function in Children With Down Syndrome
|
N/A | |
Completed |
NCT01090297 -
Continuous Positive Airway Pressure (CPAP) Mode Impact on Clinical Blood Arterial Pressure
|
N/A | |
Completed |
NCT00801671 -
Russian Study of the Effect of Continuous Positive Airway Pressure (CPAP) in Hypertension
|
Phase 3 | |
Completed |
NCT00850876 -
Heated Humidified Continuous Positive Airway Pressure and Nasal Physiology
|
N/A | |
Completed |
NCT02085720 -
Prevalence of OSAS in Chinese Elderly and Its CPAP Compliance
|
N/A | |
Recruiting |
NCT00874913 -
Study of Ocular Blood Flow in Patients With Glaucoma and/or Obstructive Sleep Apnea Syndrome (OSAS)
|
N/A | |
Completed |
NCT00156442 -
A Study to Examine the Relationship Between Sleep Apnea and Cleft Lip/Palate
|
N/A | |
Withdrawn |
NCT00156455 -
Sleep Disordered Breathing in Children With Single Ventricle Physiology
|
N/A | |
Completed |
NCT00222963 -
Pilot Study to Assess the Effectiveness of Tonsil and Adenoidectomy (T+A) in Overweight Children and Adolescents
|
N/A | |
Completed |
NCT01045499 -
LAGB as a Treatment for Morbid Obesity in Adolescents
|
N/A | |
Withdrawn |
NCT02559427 -
SPA Therapy in the Treatment of Sleep Apnea Syndrome
|
N/A | |
Completed |
NCT02995837 -
Cerebral Blood Flow and Childhood Obstructive Sleep Apnea
|
||
Completed |
NCT02522819 -
Feasibility Evaluation of CPAP in the Treatment of Obstructive Sleep Apnea Synchrone in the Acute Phase of Stroke
|
N/A |